No Data
Guizhou Sanli Pharmaceutical Co.,Ltd (SHSE:603439) CEO Hai Zhang's Holdings Dropped 8.8% in Value as a Result of the Recent Pullback
Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): The company did not implement share buybacks in December.
Gelonghui reported on January 2 that Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH) announced that from December 1, 2024, to December 31, 2024, the company did not implement any share buybacks. As of December 31, 2024, the company has cumulatively repurchased 7,869,300 shares through centralized bidding, accounting for 1.92% of the company's total share capital as of the date of this announcement. The maximum repurchase price was 14.20 yuan per share, the minimum repurchase price was 11.82 yuan per share, and the total amount paid was 99,954,426.00 yuan (excluding transaction fees).
Guizhou Sanli Pharmaceutical Co.,Ltd. (603439.SH): plans to jointly invest with professional investment institutions to establish a venture capital fund.
On December 26, the company Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SH) announced that it has recently signed a partnership agreement for the Guizhou Qianli Biomedical Venture Capital Fund Limited Partnership with its holding subsidiary Yunnan Wudi, Guizhou Zhuyin Capital Management Co., Ltd., Guiyang Industrial Development Fund Partnership (Limited Partnership), Guiyang Venture Capital Co., Ltd., and Guizhou Wudang Economic Development Zone Construction Investment Development Co., Ltd. The Fund plans to focus on investing in industries related to Biomedical, including but not limited to Biotechnology, pharmaceutical manufacturing, medical instruments, and Medical Services.
HAITONG SEC: The trend of moderate price reductions in the centralized procurement of Traditional Chinese Medicine varieties continues, and the domestic Pharmaceutical industry is expected to usher in a wave of mergers and acquisitions.
HAITONG SEC released a Research Report stating that the gentle trend of price reduction for Traditional Chinese Medicine varieties continues.
guizhou sanli pharmaceutical co.,ltd. (603439.SH): plans to acquire 22.9111% equity of Hanfang Pharmaceutical
On December 3, Gelonhui reported that guizhou sanli pharmaceutical co.,ltd. (603439.SH) announced that the company intends to acquire Mr. Deng Daixing's 22.9111% equity stake in Guizhou Hanfang Pharmaceutical Co., Ltd. (referred to as "Hanfang Pharmaceutical"). The equity transfer price for this transfer is RMB 169.83 million, to be paid in cash. As of the date before this equity transfer, Hanfang Pharmaceutical was a controlling subsidiary of the company, with the company holding 75.8928% equity stake in it; after the completion of this equity transfer, the company will hold 98.8039% equity stake in Hanfang Pharmaceutical.
guizhou sanli pharmaceutical co.,ltd. (603439.SH): Among the products currently in production and for sale by guizhou sanli pharmaceutical co.,ltd., there are no products related to snakes.
Gelonghui November 26th | Guizhou Sanli Pharmaceuticals (603439.SH) stated on the interactive platform that currently Guizhou Sanli Pharmaceuticals does not have any products related to snakes among its production and sales. Subsidiaries Guizhou Hanfang Pharmaceutical, Guizhou Dechangxiang, and Yunnan Wudizhi Pharmaceuticals have products with snake-related raw materials in their formulations.
Why Investors Shouldn't Be Surprised By Guizhou Sanli Pharmaceutical Co.,Ltd's (SHSE:603439) 30% Share Price Plunge
No Data
